BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS
ARDS is a serious inflammatory condition for which there are severe consequences with no current therapies other than supportive care.
- ARDS is a serious inflammatory condition for which there are severe consequences with no current therapies other than supportive care.
- Its genesis can be from various etiologies, with severe infection being a frequent cause.
- BioAegis is collaborating with the BARDA DRIVe Solving Sepsis program, to further develop plasma gelsolin for ARDS.
- Plasma gelsolin is critically depleted in ARDS patients and has been shown to address both injurious and infectious inflammation in multiple studies.